Test Menu Category: Genomics

Genomic testing evaluates sets of genes and gene interactions with respect to disease processes and treatment, especially applied in cancer prediction, diagnostics, prognostics and treatment selection.

Pharmacogenomics (PGx) is the use of genetic information in tailoring or predicting drug response whereas Pharmacogenetics associates drug interaction with an individual's genotype.

The coupling of genomic or genetic testing with the use of FDA-approved drugs results in a companion diagnostic where the drug targets a certain marker or genetic mutation associated with a patient's response. For a current listing of FDA approved companion diagnostics click here.


Genomics Tests

HER2 Gastric by IHC

HER2/neu breast cancer by FISH

HER2/neu gastric cancer by FISH

IDH1/IDH2 Mutation Analysis by Next Generation Sequencing

IgVH Somatic Hypermutation by Next Generation Sequencing

JAK2 Exon12 Mutation Analysis by Next Generation Sequencing

JAK2 V617F Mutation Analysis by PCR

KIT (D816V) Mutation

KRAS Mutation Analysis by Next Generation Sequencing

Lung Cancer Panel by Next Generation Sequencing

Melanoma Cancer Panel by Next Generation Sequencing

Microsatellite Instability Marker Profile by Immunohistochemistry (IHC)

MPL Exon 10 Mutation Analysis by Next Generation Sequencing

MYD88 p.L265P Mutation Analysis by Next Generation Sequencing

Myeloid Extended Mutation Analysis Panel by Next Generation Sequencing

Myeloproliferative Neoplasms Core Mutation Analysis Panel by Next Generation Sequencing

Paroxysmal Nocturnal Hemoglobinuria (PNH) - High Sensitivity by FLOW

PD-L1 by IHC

PDGFRβ Gene Rearrangement by FISH

PML RARA Short and Long form by qRT PCR, Minimal Residual Disease*

1 2 3